Table 1.

Clinical Summary of Vilazodone

Approved Indication(s):	Major Depressive Disorder in Adults
Main pharmacological effect(s):	Inhibition of serotonin reuptake and partial agonist effects at serotonin 5HT1A receptors
Formulation(s):	Solid oral tablets [10 mg, 20 mg, 40 mg]
Starting dose:	10 mg daily, with food
Dose-titration:	Increase to 20 mg daily after 7 days; further adjust dose to 40 mg daily as necessary
Effective dose range:	20–40 mg daily
Maximum dose:	40 mg daily
Key pharmacokinetic parameters:	Absorption is affected by food. Extensive hepatic metabolism, mainly by CYP3A4 Elimination half-life = 25 hours
Potential pharmacogenetic factors:	Unknown; dose adjustments may be necessary for known pharmacogenetic poor metabolizers or ultra-rapid metabolizers at CYP3A4
Interactions and dosing effects:	Maximum dose is 20 mg daily when given with strong CYP3A4 inhibitors; dose may need to be increased when given with strong CYP3A4 inducers